Zymeworks Inc.

    Jurisdiction
    Canada
    ISIN
    US98985Y1082 (ZYME)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    6 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    3 / 7

    Profile

    Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. Read full profile

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Fundamentals

    Net revenue
    €105.42M
    Gross margin
    94.8%
    EBIT
    -€70.96M
    EBIT margin
    -67.3%
    Net income
    -€63.21M
    Net margin
    -60.0%

    Statement period: - (published )

    Estimates

    Fiscal Year Net revenue Net income
    €122.62M +16.3% -€62.95M -0.4%
    €102.29M -16.6% -€96.65M +53.5%
    €137.77M +34.7% -€87.03M -10.0%

    Dividends

    No dividend payouts

    Earnings Calls

    Latest earnings call: May 2, 2024

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 451K $5.37M +165K Buy

    Add to watchlist

    Notifications